OncoMed Trying To Regroup After Cancer Stem Cell Pipeline Failures

After the Phase II failure of anti-cancer stem cell antibody tarextumab in small-cell lung cancer, another in a string of failures, execs highlight potential of other pipeline assets, including immuno-oncology targets.

OncoMed Pharmaceuticals Inc. is trying to shift focus to its earlier-stage pipeline assets following another pipeline setback – the failure of its anti-cancer stem cell antibody tarextumab, which is partnered with GlaxoSmithKline PLC, in the PINNACLE study in first-line small-cell lung cancer.

The mid-stage PINNACLE study tested tarextumab, which targets Notch 2/3, with etoposide and cisplatin or carboplatin chemotherapy, followed by maintenance...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category